Current projects

We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.

We are looking for D/P's in the following categories:

ID # Required D/P's Enrolled D/P's Remaining D/P's Inclusion Criteria
248464 15 0 15 Fresh Whole Blood from Healthy Individuals
247776 30 29 1 Pre-Selected SARS-CoV-2 Negative Nasopharyngeal Swabs from Inventory
247775 30 28 2 Pre-Selected SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
246581 20 20 0 Fresh Whole Blood from Healthy Individuals
246480 8 9 -1 HIV Positive Stability Study
245699 20 20 0 Pre-Selected HBV Samples with Viral Loads between 1,000 - 10,000,000 IU/mL
245423 40 40 0 Fresh Whole Blood from Healthy Individuals
245318 7 6 1 Pre-Selected Dengue, Zika and/or Chikungunya Positive Samples from Inventory - INC5074283
244616 1700 678 1022 SARS-CoV-2 Hologic Aptima Testing
244571 6 7 -1 Pre-Selected HBV Positive Samples from Inventory with Viral Load
244149 16 15 1 Normal Serum and Plasma Samples for Panels_Q_16847
243774 60 0 60 Pre-Selected BKV and EBV Negative Plasma Samples from Inventory - SRF_0002565
243767 450 0 450 Pre-Selected BKV and EBV Positive Plasma and Urine Samples from Inventory - SRF_0002565
242730 100 38 62 Abbott RealTime CT/NG Testing - Protocol 248B1
242729 300 0 300 Vaginal Sample Collection Protocol - Donors with Vaginitis Symptoms
242206 5000 6832 -1832 COVID-19 Testing
241492 500 40 460 Protocol: OQ-COV-PA2 - InteliSwab COVID-19 Rapid Test - 2nd visit
239962 500 41 459 Protocol: OQ-COV-PA2 - InteliSwab COVID-19 Rapid Test
239950 1000 40 960 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections - Miami
239445 4 4 0 High Volume Whole Blood Units from Healthy Donors - INC5087530
239210 88 99 -11 High Volume Whole Blood Units from Healthy Donors - INC4739105
239206 240 63 177 Prospective Whole Blood Collection from HxV Negative D/Ps
239188 500 0 500 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
237480 5 0 5 Fresh Whole Blood from HIV-1 Positive Individuals
237479 2 0 2 Fresh Whole Blood from Healthy Individuals
237354 1 1 0 Pre-Selected BKV and EBV Positive Plasma Samples from Inventory (Dual Infection)
237350 5 2 3 Pre-Selected BKV Positive Plasma Samples from Inventory
237091 11 0 11 Fresh Whole Blood from Healthy Individuals
236653 5 0 5 HIV-1 Positive Prospective Blood Collection Protocol
- 2 D/Ps with Viral Load over 2,000 cp/mL
- 1 D/P with Viral Load at around 1,000 cp/mL
- 1 D/P with Viral Load at around 2,000 cp/mL
- 1 D/P with Viral Load at around 3,000 cp/mL
236361 5 1 4 Fresh Whole Blood from Healthy (HxV Negative) D/Ps
236172 5 6 -1 Fresh Whole Blood from Healthy (HxV Negative) D/Ps
235480 19 20 -1 Pre-Selected Chlamydia Positive Samples from Inventory (Serum and Plasma)
235406 300 74 226 SARS-CoV-2 RNA Hologic Testing (Felix Chao and Peter Kim)
235321 1 0 1 Fresh Whole Blood from Healthy Donor(s)
235306 6 6 0 Pre-Selected HxV Negative Samples from Inventory
235301 6 5 1 Pre-Selected HIV Samples from Inventory with Viral Load and Specific Mutation
234803 200 198 2 Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16976)
234090 17 33 -16 Pre-Selected anti-HBs Positive Samples from Inventory
233409 12 4 8 Pre-Selected HCV Positive Samples form Inventory (K2EDTA and/or Citrate Plasma)
233408 12 14 -2 Pre-Selected HBV Positive Samples form Inventory
233218 150 8 142 IDS-21MAXCOMBO - SARS-CoV-2 Hologic Aptima Testing
233007 1000 27 973 CBC Initiative, SACQ_0002392 (INC4932295) - SRF_0002617 - Buffy Coat - BCW
231203 50 0 50 Vaginal Swab Samples From Subjects With Suspected STIs - Clinical Protocol TP-000033
231202 53 53 0 Beta Study of the Visby Sexual Health Test - Clinical Protocol TP-000516
230530 20000 1295 18705 Customer Samples kept in Biorepository (CMVG Samples, Susan Rimpel)
228548 100 102 -2 Remnant VZV Samples (IGG Negative)
228201 20000 466 19534 Customer Samples kept in Biorepository from Minneapolis Medical Research Foundation (MMRF)
227994 130 5 125 PAS-19SUST054 - HCV
227993 130 1 129 PAS-19SUST052 - HBV
227992 130 10 120 PAS-18SUST041 - Evaluation of the BD Vacutainer® K2EDTA Blood Collection Tubes with Hemogard™ Closure using Molecular Diagnostic Testing for HIV-1 Viral Load (VL) Assay
227629 50 8 42 SARS-CoV-2 Positive NP and Saliva Matched Set
227621 3 2 1 HIV-1 Positive Prospective Blood Collection Protocol:
- Three (3) D/Ps to have an HIV-1 Viral Load of:
Donor #1: 1000 copies/mL (+/- 10%)
Donor #2: 2000 copies/mL (+/- 10%)
Donor #3: 3000 copies/mL (+/- 10%)
226001 100 38 62 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
225611 10000 0 10000 A Multi Site, Longitudinal, Prospective Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
225101 1000 3 997 COVID-19 Testing; Private Office
224701 360 0 360 cX8-COV-549: Classic Repro Protocol
224534 180 124 56 SARS-CoV-2 Negative NP and Raw Saliva Matched Set
224514 600 76 524 Initiative to Screen Potential Study Candidates (SUST)
223768 12 0 12 Remnant SARS-CoV-2 Positive Dry Nasal Swabs
222843 20 0 20 Remnant SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
220541 100 42 58 Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16913)
219607 1000 9 991 COVID-19 Testing; Private Office
219219 22 21 1 Normal Serum and Plasma Samples for Panels_Q_16894, Q_16914 and Q_16913
218357 325 473 -148 Prospective Healthy Subject Blood Collection Protocol
217882 65 12 53 Prospective SARS-CoV-2 Positive Sample Collection Protocol (NPS and Saliva)
213622 2500 0 2500 Protocol: cX8-CAB-547 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
210687 7 8 -1 Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load and Genotype
210071 2500 555 1945 Protocol: cX8-CAB-533 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
208168 1000 111 889 COVID-19 Testing; Private Office
206253 60 20 40 High Volume K2EDTA Whole Blood and Plasma from Healthy Donors
205506 200 0 200 Urine and Saliva Matched Set from Healthy D/Ps
-100 subject collected in the morning until 9 AM
-100 subjects collected in the afternoon after 4 PM
205083 10 0 10 Prospective Urine Collection from Healthy Donors
204811 150 190 -40 SARS-CoV-2 Negative Raw Saliva Samples from Inventory
204810 40 0 40 Prospective SARS-CoV-2 Negative Raw Saliva Samples
Ship same day
204808 50 0 50 SARS-CoV-2 Negative Nasal Swabs from Inventory
202732 1000 99 901 PROTOCOL 274C3 - Clinical Evaluation of the Xpert® Xpress CoV-2/Flu/RSV XC Test on the GeneXpert Dx and Infinity Systems in Laboratory and Near-Patient Testing Environment
201758 130 48 82 PAS-18SUST033 - Validation of the Clinical Performance of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure in Comparison with the Greiner Vacuette® K2EDTA Gel Tubes for Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
200508 1000 60 940 COVID-19 Testing; Private Office
198399 220 127 93 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
198391 500 0 500 Prospective Healthy Subject Blood Collection Protocol
195801 220 0 220 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
195775 20000 1380 18620 Customer Samples kept in Biorepository from HBcT2 [JRID#93116]
194268 150 0 150 Prospective Nasal Swab Collection Protocol
194052 21 0 21 HxV Negative K2EDTA Plasma from Inventory - SRF_TBA
193266 200 130 70 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
191880 875 600 275 Prospective Healthy Subject Blood Collection Protocol
190737 5000 15 4985 SARS-CoV-2 Survey (PT)
184026 700 542 158 SARS-CoV-2 RNA Hologic Testing
182696 1000 355 645 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections
180141 15 15 0 Normal Serum and Plasma Samples for Panels_Q_16847
178076 130 79 51 PAS -19SUST046 - Evaluation of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure for Repeatability and Reproducibility of Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
176622 10 0 10 Normal Serum Samples with Unit Back-Ups
DP willing to donate a Whole Blood Unit
176111 25 0 25 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps - SRF_6026_Q16802
175884 500 97 403 SARS-CoV-2 RNA Hologic Testing
175792 10000 116 9884 COVID-19 Testing; Tu Cara me Sue
175398 10000 552 9448 COVID-19 Testing; Crew-Royal Caribbean Cruises Ltd
175121 1000 27 973 CBC Initiative
174026 1000 122 878 COVID-19 Testing; Private Office
173768 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Saliva, Sputum, Nasal, Pharyngeal, Blood and/or Finger Stick Specimens from SARS-CoV-2 positive subjects
173505 20 20 0 SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
172886 1000 1018 -18 COVID-19 Testing; Private Office
169711 400 398 2 SARS-CoV-2, Nasal swab, Nasopharyngeal Swab, Oropharyngeal swab and Saliva
169440 300 110 190 Remnant Pregnancy Samples
169439 100 258 -158 Remnant HSV Samples
168884 50 0 50 Evaluation of the prognostic performance of HostDx ViralSeverity to predict outcomes of SARS-CoV-2
168867 1000 320 680 COVID-19 Testing; Private Office
168264 10 10 0 SARS-CoV-2 Negative Nasal, Nasopharyngeal Swab
168078 50 2 48 Prospective COVID-19 Positive Sample Collection Protocol (NPS and Raw Saliva)
165868 1000 127 873 COVID-19 Testing; Private Office
163904 1000 919 81 COVID-19 Testing; Private Office
162417 35 34 1 Fresh Whole Blood from Healthy (HxV Negative) D/Ps - SRF_5868_4
161853 100 861 -761 Abbott RealTime CT/NG Testing, Cepheid_248C1& 248C3
157934 1000 803 197 COVID-19 Testing; Private Office
156661 10000 1710 8290 COVID-19 Testing; Private Office
155679 30 310 -280 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
154904 10000 40 9960 COVID-19 Testing; Private Office
154536 1000 458 542 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 500 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
153900 10000 31303 -21303 COVID-19 Testing, Florida Department of Health
152854 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
152825 5000 106452 -101452 COVID-19 Testing
152764 9 27 -18 HCV Viral Load Testing
152672 5000 40 4960 Follow-UP_COVID-19 Testing_Blood and Nasopharyngeal Swabs
152645 24 0 24 Female Vaginal Sample Collection Protocol for Panel Development
152331 5000 1654 3346 COVID-19 Testing
151990 195 13 182 Pre-Selected CMV Positive Samples form Inventory (SRF_5628 - STING Project)
151989 195 50 145 Pre-Selected CMV Negative Samples form Inventory (SRF_5628 - STING Project)
151681 5000 3 4997 Refer to Processing Instructions @ Attachment Tab
151476 1 0 1 HIV Group and Subtype Testing
150014 500 64 436 Seegene Validation Collection Protocol from Male and Female Samples
149547 5000 180 4820 Refer to Processing Instructions @ Attachment Tab
TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB
149472 100 69 31 HIV-2 Prospective Blood Collection Protocol - SRF_5628
149267 200 135 65 Prospective Nasopharyngeal Swab Collection- SRF_5469
148791 5000 24 4976 Refer to Processing Instructions @ Attachment Tab
146391 92 0 92 High Volume Whole Blood Collection to Evaluate The Long-Term Stability of Roche cfDNA tubes - SRF_5743
145574 5000 65 4935 Refer to Processing Instructions @ Attachment Tab
144888 195 1277 -1082 Pre-Selected Negative Samples form Inventory (SRF_5628 - STING Project (SRF_0002000))
144620 5000 35 4965 Refer to Processing Instructions @ Attachment Tab
144001 100 825 -725 Pediatric EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM):
- 50 samples from subjects with the ages of 2 through 12 years of age AND
- 50 samples from subjects with the ages of 13 through 21 years of age
- Gender: Male or Female
- Minimum Volume: 1.5 mL (1.2 mL's)
- Storage Temperature: Samples must have been frozen at -20°C or below within 2 days of collection.
143401 1500 1158 342 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 3000 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
142755 5000 70 4930 Refer to Processing Instructions @ Attachment Tab
141914 1000 7 993 HIV Initiative
141493 5000 35 4965 HCV Viral Load and Genotype Survey (PT)
141491 5000 15 4985 HBV Viral Load Survey (PT)
141490 5000 35 4965 HIV Viral Load Survey (PT)
140923 5000 60 4940 Refer to Processing Instructions @ Attachment Tab
140922 5000 35 4965 Refer to Processing Instructions @ Attachment Tab
140530 5000 10 4990 Rubella IgG (AAB - PT)
140528 5000 6 4994 ToRCH (AAB - PT)
139409 5000 75 4925 Pregnancy (PT)
137933 5000 0 5000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
137683 930 235 695 Preeclampsia Blood Collection Protocol from Asymptomatic and Symptomatic Populations
136025 300 357 -57 EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM)
135041 100 0 100 GC/CT/MG/TV prospective collection at Budapest
134700 60 25 35 Abbott Real Time EBV and BKV Testing - SRF_5465
134182 100 80 20 HBV/Mayaro Samples from Colombia
133225 200 274 -74 Prospective HCV Positive serum collection
129688 200 123 77 EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia
129538 1000 309 691 RPR Initiative
128402 1000 64 936 CBC Initiative
124266 5000 143 4857 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire
122931 5000 1510 3490 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
122654 5000 171 4829 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland
120851 140 26 114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
120409 300 84 216 Matched Prospective Collection Protocol from an HCV, HBsAg and/or RPR Positive Reactive Population
109382 100 32 68 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
109381 300 6 294 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
108692 1000 943 57 HxV Testing Initiative
102772 50 26 24 Random Cadaveric Samples
102419 1000 448 552 Samples on hold for future shipments to China
98830 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples
98084 1000 562 438 CBC Qualifying Job Request
96278 195 185 10 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
96055 40 1684 -1644 Hologic Panels for HIV and HCV
94841 500 1 499 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR
93116 700 734 -34 Prospective Blood Collection Protocol from D/Ps with Signs & Symptoms or at High Risk for Hepatitis
80997 5000 428 4572 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
79734 100 0 100 Prospective Zika Screening and Longitudinal Sample Collection Protocol
78138 300 140 160 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
78137 300 414 -114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
74261 10000 0 10000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
68258 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
66495 200 225 -25 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World for Dengue
63869 1 2 -1 Negative Material for Panel Member
63868 1000 555 445 Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau
56717 20000 0 20000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples
55075 10000 28 9972 Beta HCG Matched Set Prospective Blood Collection Protocol
54664 200 148 52 Random Cadaveric Samples
38626 300 143 157 Prospective Sample Collection of Specifically Diagnosed D/Ps with Diseases of the Liver or Related Complications:
·50 x Alcoholic liver disease
·30 x Autoimmune hepatitis
·30 x Fatty liver disease
·30 x Non-alcoholic Steatohepatitis (NASH)
·30 x Primary Biliary Cirrhosis (PBC)
27615 15000 633 14367 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World
26761 10000 482 9518 HIV Positive Time Stability Whole Blood Collection Protocol
10694 3000 2234 766 HCV Longitudinal Prospective Blood Collection Protocol
10693 3000 369 2631 HBV Multi-Point Prospective Blood Collection Protocol
8568 300 1528 -1228 Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV)



BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.

You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.



Contact us to learn more